Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a “massive opportunity.” It’s called targeted radiopharmaceutical therapy. It essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. RBC Capital Markets sees a $25 billion market opportunity for the space. Four acquisitions in the space were announced in just the last several months. The latest was by Novartis, which already has two targeted radiotherapies on the market. Pluvicto treats a certain type of advanced prostate cancer, while Lutathera targets neuroendocrine tumors.
Read the full article: This Up-and-Coming Cancer Treatment Could Be a $25B Market Opportunity — It’s Already a Hotbed for M&A //
Source: https://www.cnbc.com/2024/05/23/this-up-and-coming-cancer-treatment-could-be-a-25-billion-market-opportunity.html